| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 46,685 | 42,499 | ||
| Short-term investments | 35,900 | 918 | ||
| Research and development tax credits receivable | 808 | 1,079 | ||
| Prepaid expenses | 2,577 | 748 | ||
| Other receivables | 700 | 924 | ||
| Total current assets | 86,670 | 46,168 | ||
| Operating lease right-of-use assets | 944 | 1,090 | ||
| Property and equipment | 136 | 159 | ||
| Total assets | 87,750 | 47,417 | ||
| Accounts payable and accrued liabilities | 10,041 | 8,768 | ||
| Operating lease liabilities | 483 | 515 | ||
| Total current liabilities | 10,524 | 9,283 | ||
| Operating lease liabilities, net of current portion | 519 | 641 | ||
| Senior secured convertible notes | 56,206 | 55,238 | ||
| Total liabilities | 67,249 | 65,162 | ||
| Common shares, no par value, unlimited shares authorized, 85,169,344 shares issued and outstanding as of september 30, 2025, 53,353,984 shares issued and outstanding as of december 31, 2024 | 311,776 | 288,263 | ||
| Pre-funded warrants - 16,412,925 issued and outstanding as of september 30, 2025 and 12,910,590 as of december 31, 2024 | 55,649 | 53,076 | ||
| Additional paid-in capital | 66,270 | 42,188 | ||
| Accumulated deficit | -413,194 | -401,272 | ||
| Total shareholders' (deficit) equity | 20,501 | -17,745 | ||
| Total liabilities and shareholders' equity | 87,750 | 47,417 | ||
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)